Not So Different: A Podcast from The Center for Biosimilars Not So Different: a Podcast from The Center for Biosimilars

In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.

On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars and the feasibility of switching to them.

In April, The Center for Biosimilars had the pleasure of attending Festival of Biologics USA in San Diego, California, where we got to cover major presentations and discuss the global biosimilar industry with valued experts in the space. One of those experts is joining us today to discuss takeaways from the meeting: Dracey Poore, director of biosimilars at Cardinal Health, who presented on market insights that came out of Cardinal Health's annual biosimilar report.

Prior to her work with Cardinal Health, Dracey worked for Organon and Merck as associate director of US oncology biosimilar marketing strategy. The Cardinal Health biosimilar report is a hotly anticipated report for the industry, presenting on how the market is developing as well as evolving prescriber trends and perspectives on these medications. We are pleased to have Dracey for her first guest appearance on Not So Different!

On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.

On this episode of Not So Different, The Center for Biosimilars® discusses all the conference coverage, adalimumab data, and market insights to come out of the biosimilar dermatology space in March 2024.

On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.